Anticoagulants in non-valvular atrial fibrillation : Synthesis [printed text] / Hans Van Brabandt  , Author ; Lorena San Miguel , Author ; Nicolas Fairon , Author ; Bert Vaes, Author ; Séverine Henrard, Author ; Anelia Boshnakova, Author ; Rob Cook, Author ; Rob Davies, Author ; Aditi Karnad, Author ; Alan Lovell, Author ; Cécile Dubois , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2016 . - 22 p. : ill., ; A4. - ( KCE Reports. Health Technology Assessment (HTA); 279Cs) . ISSN : D/2016/10.273/100 : € 0,00 Study 2015-05 Languages : English ( eng)
| Descriptors: |
Indexation
2015-05 ; Anticoagulants ; Atrial Fibrillation ; Belgium ; Cost-Benefit Analysis ; Physician's Practice Patterns ; Practice Guidelines as Topic ; R279 ; Secondary Prevention
Classification
QV 193 Anticoagulants
|
| Contents note: |
FOREWORD -- KEY MESSAGES 2 -- SYNTHESE 4 -- 1. OBJECTIVES OF THIS STUDY 6 -- 2. ATRIAL FIBRILLATION 6 -- 2.1. A SILENT DISORDER WITH POTENTIALLY SERIOUS CONSEQUENCES 6 -- 2.2. ASSESSMENT OF THE THROMBOEMBOLIC RISK 7 -- 3. EFFICACY OF ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION 8 -- 3.1. VITAMIN K ANTAGONISTS 8 -- 3.2. NOVEL ORAL ANTICOAGULANTS (NOACS) 8 -- 3.3. COMPARISON OF THE EFFICACY OF VKAS AND NOACS 9 -- 4. PRACTICAL: PRESCRIBE ANTICOAGULANTS OR NOT? 11 -- 4.1. FINDING THE BALANCE BETWEEN THE RISK OF ISCHEMIC AND HAEMORRHAGIC STROKE.11 -- 4.2. OVERTREATMENT 12 -- 4.3. UNDERTREATMENT 12 -- 4.4. SPECIAL CASE: PATIENTS WITH A CHA2DS2-VASC SCORE = 1 (FOR MEN) AND = 2 (FOR WOMEN) 13 -- 4.5. ADDITIONAL OBSERVATIONS 14 -- 5. MONITORING A PATIENT ON ANTICOAGULANTS 15 -- 5.1. MONITORING COAGULATION 15 -- 5.2. MONITORING COMPLIANCE 15 -- 5.3. A NEW FORM OF UNDERTREATMENT WITH NOACS 16 -- 5.4. REVERSIBILITY OF THE ANTICOAGULANT EFFECT AND ANTIDOTES 16 -- 6. ECONOMIC ASPECTS 17 -- 6.1. REIMBURSEMENT OF NOACS IN BELGIUM 17 -- 6.2. ECONOMIC EVALUATIONS 18 -- 7. CONCLUSIONS 19 -- 7.1. ANTICOAGULANTS OR NOT? 19 -- 7.2. VKA OR NOAC 19 -- 7.2.1. Advantages of NOACs compared to VKAs 19 -- 7.2.2. Disadvantages of NOACs compared to VKAs 19 -- 7.2.3. Conclusion 20 |
| Link for e-copy: |
https://doi.org/10.57598/R279CS |
| Format of e-copy: |
PDF (847 Kb) |
| Record link: |
https://kce.docressources.info/index.php?lvl=notice_display&id=3967 |
|  |
Anticoagulants in non-valvular atrial fibrillation / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
